Medical &Health

BMRC clears Indian Covaxin’s clinical trials in Bangladesh

Bangladesh Medical and Research Council (BMRC) has approved in principle the clinical trials of Indian Covid-19 vaccine Covaxin in Bangladesh.

BMRC Chairman Prof Dr Syed Modasser Ali shared the information with UNB on Tuesday.

On July 18, Covaxin, a Coronavirus vaccine jointly developed by Bharat Biotech and the Indian Council of Medical Research (ICMR), got the clearance for its clinical trials in Bangladesh, he said.

Contract Research Organization (CRO) icddr,b had applied seeking permission for the clinical trials of the Indian vaccine in Bangladesh a few months ago.

After the review of necessary documents, the vaccine got clearance from the BMRC, said Dr Modasser.

He, however, said the approval of the Directorate General of Drug Administration (DGDA) will be needed to start the clinical trials of Covaxin in the country.

India has planned to facilitate its clinical trials in Bangladesh in a bid to enhance the recognition of indigenous coronavirus vaccine, Covaxin, according to Indian media reports.

India has not supplied any Covaxin doses to Bangladesh so far.

Source: United News of Bangladesh